Vascular Biogenics Ltd. (VBLT)

Market Cap	15.40M
Revenue (ttm)	545,000
Net Income (ttm)	-24.52M
Shares Out	70.50M
EPS (ttm)	0.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	916,469
Open	0.225
Previous Close	0.230
Day's Range	0.213 - 0.230
52-Week Range	0.101 - 2.200
Beta	0.68
Analysts	Hold
Price Target	5.50 (+2,417.16%)
Earnings Date	May 26, 2023

About VBLT

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 1, 2014
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: VBLT

Financial Performance

In 2022, VBLT's revenue was $658,000, a decrease of -14.32% compared to the previous year's $768,000. Losses were -$32.30 million, 7.97% more than in 2021.

Analyst Forecast

According to 3 analysts, the average rating for VBLT stock is "Hold." The 12-month stock price forecast is $5.5, which is an increase of 2,417.16% from the latest price.

Price Target

$5.5

(2,417.16% upside)

Analyst Consensus: Hold